PMI: Taking Bold Action for Global Change: a Conversation on Tobacco Today and Transformation for Tomorrow
During the 2018 Concordia Annual Summit, taking place in September 24 & 25 in New York, André Calantzopoulos, CEO of Philip Morris International, delivered a speech highlighting the need to have a dialogue between the industry, leaders, policy-makers, scientists, medical, and public health professionals in order to provide the 1.1 billion people who smoke with better alternatives to cigarettes.
The Concordia Annual Summit, which coincides with the United Nations General Assembly (UNGA) meeting, convenes the world’s most prominent business, government, and nonprofit leaders to foster dialogue and enable effective partnerships for positive social impact.
The remarks by André Calantzopoulos follow:
“I'm the Chief Executive Officer of a tobacco company. I’m here today because, as global leaders come together in New York for the United Nations General Assembly, this is the time and place to discuss today's problems and their potential solutions.
“Smoking tobacco is a behavioral risk factor for Non-Communicable Diseases (NCDs). According to the WHO, 40 million people die each year from NCDs. And tobacco smoking accounts for 7.2 million of those deaths. Public health experts project that the global burden of smoking-related disease will continue to increase in the future.
“This week is about different sectors coming together to take bold action for global progress. That's why PMI is here. We are asking global leaders to enter into an honest, transparent dialogue with us. We are radically transforming our company to deliver a future without cigarettes. We have a duty to help create a better world for the more than 1 billion men and women who smoke today. We are committed to these people—and to the people who care about them. Their access to better choices means a better life for them and a better future for the sustainability of our planet, our economies and our communities.
“Our vision for a smoke-free future, which means a future without cigarettes, is one that many share. This is why PMI is pioneering in the smoke-free category — to deliver a world without cigarettes. Our ambition is to convince all adult smokers who might otherwise continue smoking cigarettes to switch to smoke-free products, which are a much better alternative for them.
“Yes, in an ideal world, all smokers should quit tobacco and nicotine consumption altogether. We fully agree with this. This is the lowest-risk scenario compared with cigarette smoking. But we don't live in a world where this can or will happen automatically—or anytime soon.
“Even with increasing prevention and cessation efforts, there are still more than 1 billion people who currently smoke cigarettes. And according to the WHO, there will still be more than a billion people who choose to smoke in 2025.
“These people are your constituents, your customers, and perhaps, your friends and family. This is reality. It must be met with an ambitious effort to offer these people help by making less harmful products available: allowing them to make better and informed choices.
“We know smoking tobacco causes disease. We also know that while not risk free, tobacco and nicotine are not the primary cause of smoking-related NCDs. In fact, the primary cause is the act of burning tobacco and inhaling the smoke.
“Science, innovation and technology have allowed the development of a new category of products that don't involve combustion or smoke. Their aerosol contains a small fraction of the toxicants that appear in cigarette smoke. You may know these alternatives as e-cigarettes and heated tobacco products.
“We spent years to develop and scientifically assess the risk reduction potential of such products compared with cigarette smoking. Every single pre-clinical and clinical study we've conducted confirm their potential to have a significant, positive impact on public health.
“And there's a growing body of independent studies, including from government laboratories, that points towards the same conclusions.
“Of course, there are skeptics who point to the past and express doubts about our sincerity and our science. I can't change the past. My focus is on changing the future. Can you imagine the criticism I would face if years from now, it was discovered that we had better options for people that smoke but left them in the laboratory?
“There’s growing recognition, in several countries like the U.K. and the U.S., that innovative smoke-free alternatives to cigarettes are likely to be less harmful than continued smoking. These countries view them as an important tool to complement public health policies focused on prevention and cessation.
“To be clear, I'm not saying that smoke-free products are safe or a perfect solution. I am saying that switching to scientifically substantiated alternatives is a better choice than continuing to smoke. Many smokers around the world recognize that these innovations work for them. Adoption rates point to a promising future.
“There is every reason to be optimistic that these alternatives are a viable and additional path to help reduce the harm caused by smoking — a path that complements regulatory restrictions on cigarettes.
“I’m aware of the criticisms around our motivations. But I’m asking you to look at the science and listen to the voices of men and women who smoke. We've invested billions of dollars in research, development, and scientific assessment of smoke-free products. The results are published and available for review. In just three years, we've made these products available to adult smokers in 40 countries.
“Nearly 6 million men and women have already stopped smoking and switched to our heated tobacco product.
“Now we need to come together and discuss what society can and should do next. In my view we need to evaluate not whether the world’s billion smokers should have access to better alternatives to cigarettes, but how. How can we implement the right regulatory framework to maximize switching to better products while minimizing any unintended public health consequences?
“Let me be clear. The best choice is never to start using a tobacco or nicotine product at all. And PMI fully supports policies to prevent young people from initiating the use of any nicotine-containing product.
“We're committed to the Global Goals for Sustainable Development. Clearly, the greatest contribution we can make to society is to replace cigarettes with less harmful alternatives.
“True change and development requires partnerships—this is one of the UN's stated goals. Just as other sectors have brought their best ideas for solutions and innovations, so have we. We've listened to the call from the UN and global leaders to leverage technology in order to drive progress. In every other sector, when better options emerge, everyone works together to make them available as quickly as possible.
“However in my sector, society is both polarized and paralyzed. We urgently need an open dialogue. We are ready and willing to talk with people across all sectors and of all points of view, including those who disagree with us. My ask is for everyone here today to carefully consider the role that smoke-free alternatives can play in achieving global health goals.
“Today, better options are available for men and women who smoke. For these billion people, it's our responsibility to ensure this moment of transformation does not pass them by.
“We know we can't achieve this alone. We need the voices of you and people like you, to be part of the conversation about how we can realize the promise of better options for people who smoke.”
Philip Morris International: Who We Are
We are a leading international tobacco company engaged in the manufacture and sale of cigarettes and other nicotine-containing products in markets outside the United States of America. We’re building our future on smoke-free products that are a much better consumer choice than continuing to smoke cigarettes. Through multidisciplinary capabilities in product development, state-of-the art facilities and scientific substantiation, we aim to ensure that our smoke-free products meet adult consumer preferences and rigorous regulatory requirements. Our vision is that these products ultimately replace cigarettes to the benefit of adult smokers, society, our company and our shareholders. For more information, see www.pmi.com and www.pmiscience.com.
Philip Morris International media office
T: +41 (0)58 242 4500
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Hilton Launches New Brand, Signia Hilton, Delivering Sophisticated Travel While Reimagining Meetings and Events22.2.2019 17:00:00 | Pressemelding
Hilton (NYSE: HLT) today announced the launch of Signia Hilton, its dynamic, new meetings-and-events-focused brand. The portfolio of hotels is setting out to transform the industry for meeting professionals and sophisticated business travelers by infusing state-of-the-art technology and design into every aspect of the guest experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005071/en/ The brand further reinforces Hilton’s commitment to innovation that meets the evolving needs of today’s travelers and will bring premium experiences to top urban and resort destinations around the world. “In our 100th year of hospitality, we are more focused than ever on providing exceptional experiences to all of our guests – and that includes evolving those experiences to meet their changing needs,” said Christopher J. Nassetta, president and CEO, Hilton. “We are proud to launch Signia Hilton, which exemplifies our innovative sp
Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans22.2.2019 16:30:00 | Pressemelding
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced today that it has received CE mark approval for 1.5T and 3T full-body magnetic resonance imaging (“MRI”) conditional labeling for the Axonics r-SNM® System. The Axonics r-SNM System is the only implantable SNM system that has received full-body MRI conditional labeling for sale in Europe1. Raymond W. Cohen, Chief Executive Officer of Axonics, said, “Without this labeling, any patient requiring an MRI scan on any body part below the head must have their neurostimulator surgically explanted prior to the MRI scan, resulting in an additional surgery for the patient and additional costs to patients and the healthcare system. This authorization of full-body MRI scans in Europe is another important milestone for Axonics, differentiating our te
Fantastec Joins Forces with Arsenal FC Launching Official Blockchain Collectibles App22.2.2019 14:30:00 | Pressemelding
Fantastec announced today its first football licensing agreement with Premier League club Arsenal FC for a new blockchain authenticated collectibles app called Fantastec SWAP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005277/en/ Arsenal players appear on Fantastec SWAP in official licensing deal (Graphic: Business Wire) London-based Fantastec is a leading sports fan technology innovator, and its blockchain based ‘SWAP’ app will have broad appeal to global sports fans, gamers and sports card collectors alike. Fantastec SWAP unlocks unique and authentic club content through the app, like player autographs and exclusive footage. With its innovative blockchain technology, fans around the world can now discover, collect and swap officially licensed club collectibles with other fans with complete trust. “Fantastec SWAP is a game-changer for international football fans as well the sports collectibles industry,” commented
Volkswagen Protects Virtual Key Sharing App with Trustonic Application Protection22.2.2019 13:42:00 | Pressemelding
Volkswagen is working with mobile cyber security leader Trustonic to enable customers to use smartphones to access their vehicles, and to securely share their digital car keys to grant access to others via a smartphone app. Volkswagen is using the Trustonic Application Protection (TAP) platform to secure the mobile app and ensure that sensitive information and key transfer requests are securely displayed to, and approved by, a real authenticated user on a trusted device and not by hackers or malware simulating a user or device. “The smartphone is becoming the vehicle key of the future and our We Connect service is the interface for this today in the new Volkswagen Passat,” comments Alf Pollex, Head of Infotainment and Connected Car at Volkswagen AG. “The user installs the We Connect app on their smartphone which is then authorized via the infotainment system with a Transaction Number. The Mobile Key will be compatible with Android-based Samsung devices. No mobile network connection is
Mundipharma EDO GmbH: US FDA grants Orphan Drug Designation for etoposide toniribate in relapsed/refractory biliary tract cancer22.2.2019 13:30:00 | Pressemelding
Mundipharma EDO GmbH, part of the Mundipharma network of independent associated companies, and Imbrium Therapeutics L.P., an operating subsidiary of Purdue Pharma L.P., today announced that the US FDA has granted Orphan Drug Designation (ODD) to etoposide toniribate for the treatment of relapsed/refractory biliary tract cancer, also known as cholangiocarcinoma.3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190222005126/en/ Biliary tract cancer is a rare tumour with approximately 8,000 patients diagnosed in the US every year and 10,571 in Europe.4,5 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US. Radical surgery is the only curative treatment for biliary tract cancer but, in most cases, the cancer is inoperable. Patients who fail first-line chemotherapy have limited treatment options and the standard of
Lenovo Data Center Group Delivers Broad Edge Computing Portfolio, Expands Investments in IoT22.2.2019 13:13:00 | Pressemelding
Next week at MWC Barcelona, Lenovo Data Center Group (DCG) will showcase continued investments in its solutions supporting IoT and edge computing as part of its IoT growth plan over the next few years. Building on the momentum of its fifth consecutive quarter of profit growth, Lenovo DCG is building a portfolio that takes infrastructure to where the data is, whether that be in the traditional data center, in the cloud or increasingly, at the edge. Today, around 10 percent of enterprise-generated data is created and processed outside a traditional centralized data center or cloud. By 2022, Gartner predicts this figure will reach 75 percent. This migration is driving increased concerns around data privacy, security and regulations coupled with challenges of latency, bandwidth and downtime. Lenovo is addressing these challenges by creating a broad portfolio of edge computing offerings that address the different ways that customers want to deploy edge computing solutions for IoT use cases.